f Vutrisiran for Transthyretin Amyloidosis Cardiomyopathy

References

1. ReamS. MaJ. RodriguezT. Ethnic/racial differences in risk factors and clinical outcomes among patients with amyloidosis.Am. J. Med. Sci.2023365323224110.1016/j.amjms.2022.12.009 36543303
   [Google Scholar]
2. IsathA. CorreaA. SirokyG.P. Trends, burden, and impact of arrhythmia on cardiac amyloid patients: A 16‐year nationwide study from 1999 to 2014.J. Arrhythm.202036472773410.1002/joa3.12376 32782646
   [Google Scholar]
3. AngS.P. ChiaJ.E. DeshmukhA.J. Efficacy and clinical outcomes of catheter ablation for atrial arrhythmia in cardiac amyloidosis.Heart Rhythm202522386586710.1016/j.hrthm.2024.08.025 39151713
   [Google Scholar]
4. BensonM.D. BuxbaumJ.N. EisenbergD.S. Amyloid nomenclature 2018: Recommendations by the International Society of Amyloidosis (ISA) nomenclature committee.Amyloid201825421521910.1080/13506129.2018.1549825 30614283
   [Google Scholar]
5. CastañoA. NarotskyD.L. HamidN. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.Eur. Heart J.201738382879288710.1093/eurheartj/ehx350 29019612
   [Google Scholar]
6. González-LópezE. Gallego-DelgadoM. Guzzo-MerelloG. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.Eur. Heart J.201536382585259410.1093/eurheartj/ehv338 26224076
   [Google Scholar]
7. GillmoreJ.D. JudgeD.P. CappelliF. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.N. Engl. J. Med.2024390213214210.1056/NEJMoa2305434 38197816
   [Google Scholar]
8. AimoA. CastiglioneV. RapezziC. RNA-targeting and gene editing therapies for transthyretin amyloidosis.Nat. Rev. Cardiol.2022191065566710.1038/s41569‑022‑00683‑z 35322226
   [Google Scholar]
9. AngS.P. ChiaJ.E. MukherjeeD. Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathy.Heart Fail. Rev.2025Epub ahead of print10.1007/s10741‑025‑10502‑5 40056371
   [Google Scholar]
10. BensonM.D. Waddington-CruzM. BerkJ.L. Inotersen treatment for patients with hereditary transthyretin amyloidosis.N. Engl. J. Med.20183791223110.1056/NEJMoa1716793 29972757
    [Google Scholar]
11. MaurerM.S. KaleP. FontanaM. Patisiran treatment in patients with transthyretin cardiac amyloidosis.N. Engl. J. Med.2023389171553156510.1056/NEJMoa2300757 37888916
    [Google Scholar]
12. HellenbartE.L. IpemaH.J. Rodriguez-ZiccardiM.C. KrishnaH. DiDomenicoR.J. Disease‐modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications.Pharmacotherapy202545212414410.1002/phar.4639 39714070
    [Google Scholar]
13. SekijimaY. SousaL. Pathogenesis, manifestations, diagnosis, and management of CNS complications in hereditary ATTR amyloidosis.Amyloid2024202411210.1080/13506129.2024.2435573 39627935
    [Google Scholar]
14. AdamsD. TournevI.L. TaylorM.S. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.Amyloid2023301182610.1080/13506129.2022.2091985 35875890
    [Google Scholar]
15. FontanaM. BerkJ.L. GillmoreJ.D. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy.N. Engl. J. Med.20253921334410.1056/NEJMoa2409134 39213194
    [Google Scholar]
16. MaurerM.S. SchwartzJ.H. GundapaneniB. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.N. Engl. J. Med.2018379111007101610.1056/NEJMoa1805689 30145929
    [Google Scholar]
17. MerliniG. Vutrisiran for ATTR amyloidosis with cardiomyopathy.N. Engl. J. Med.20253921838410.1056/NEJMe2411602 39752304
    [Google Scholar]
18. MasoudiF.A. Vutrisiran for cardiomyopathy associated with transthyretin amyloidosis.2024Available from: https://www.jwatch.org/na57895/2024/09/04/vutrisiran-cardiomyopathy-associated-with-transthyretin
19. Vutrisiran (Amvuttra)CADTH Reimbursement Recommendation: Indication: For the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis.Ottawa, ONCanadian Agency for Drugs and Technologies in Health2024
    [Google Scholar]